News

The European Commission has expanded its approval of Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to treat children with cystic fibrosis (CF) as young as 6 who have the most common type of CF-causing mutation. The Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. approved a similar expansion.

Peptilogics has won an award to conduct research for two antibacterial peptides as a first-line therapy to fight antibiotic-resistant bacteria in the lungs of people with cystic fibrosis (CF). According to a press release, the award, by the Cystic Fibrosis Foundation, will support further preclinical research of…

Researchers at The Rockefeller University in New York City have determined how two medications used to treat cystic fibrosis (CF), lumacaftor and tezacaftor, interact with the CFTR protein. The results suggest that these medicines bind to the protein — usually impaired or missing in people with CF — and…

The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward  developing a new gene therapy for cystic fibrosis (CF). SalioGen is working to advance a novel type of gene therapy, called Gene Coding, which is accomplished using the company’s…

Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan drug status to SPL84-23, SpliSense’s investigational therapy for cystic fibrosis (CF) patients carrying a common disease-causing splicing mutation. The designation is given to treatment candidates with the potential to be safe…

BiomX has been given up to $5 million to support a clinical trial of BX004, a phage therapy to fight Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). Trial funding, awarded by the Cystic Fibrosis Foundation (CFF), marks one of several recent studies into phage therapy…

Airway cells in cystic fibrosis (CF) were more susceptible to death due to the buildup of iron and their reduced antioxidant ability, a study suggested. These findings support further research into the use of iron-binding chelators and antioxidants as potential CF therapies, the scientists said. The study, “…

Cystic Fibrosis News Today brought you daily coverage of the latest scientific findings, treatment developments, and clinical trials related to cystic fibrosis (CF) throughout 2021, a year still marked by the COVID-19 pandemic. We look forward to reporting more news to patients, family members, and caregivers dealing with CF during 2022.

EnBiotix has raised $11 million in financing that will help fund clinical testing of ColiFin (inhaled colistimethate sodium) and murepavadin, two antibiotics that may be useful for controlling lung infections in people with cystic fibrosis (CF). Some of the funding was from the Cystic Fibrosis Foundation,…

A cluster of Mycobacterium abscessus (M. abscessus), a difficult-to-treat bacteria that causes lung damage, particularly in people with cystic fibrosis (CF), was identified in the southeastern Florida, a recent study reported. According to its findings, patients who tested positive for a nontuberculous mycobacteria (NTM) infection, including M. abscessus, were…